Wolf Group Capital Advisors’s GSK GSK Stock Holding History

Wolf Group Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-25,436	Closed	-$1.22M	–	84
2018 Q4	$1.22M	Buy	25,436 +12	+0%	+$591	0.9%	37
2018 Q3	$1.28M	Sell	25,424 -1,788	-7%	-$90.8K	0.83%	43
2018 Q2	$1.37M	Buy	27,212 +1,462	+6%	+$73.6K	0.89%	48
2018 Q1	$1.26M	Buy	25,750 +4,091	+19%	+$191K	0.83%	51
2017 Q4	$960K	Sell	21,659 -185	-0.8%	-$8.55K	0.6%	64
2017 Q3	$1.12M	Sell	21,844 -9,883	-31%	-$501K	0.78%	51
2017 Q2	$1.71M	Sell	31,727 -2,317	-7%	-$124K	1.31%	32
2017 Q1	$1.79M	Sell	34,044 -3,013	-8%	-$153K	1.18%	35
2016 Q4	$1.78M	Sell	37,057 -11,469	-24%	-$567K	1.2%	34
2016 Q3	$2.62M	Sell	48,526 -9,507	-16%	-$521K	1.82%	14
2016 Q2	$3.14M	Buy	58,033 +43	+0.1%	+$2.27K	2.32%	6
2016 Q1	$2.94M	Buy	57,990 +8,419	+17%	+$419K	2.21%	10
2015 Q4	$2.5M	Buy	+49,571	New	+$2.53M	1.86%	11

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Wolf Group Capital Advisors's GSK Position: Q1 2019 in Review

Wolf Group Capital Advisors sold out of GSK (GSK) in Q1 2019, closing a stake of 25,436 shares — an estimated $1.22M sold.

Wolf Group Capital Advisors first reported a position in GSK in Q4 2015 and held it in 13 quarters. The position peaked at $3.14M in Q2 2016. 848 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

Wolf Group Capital Advisors reported no remaining GSK position as of Q1 2019 after selling out during the quarter.
Wolf Group Capital Advisors sold 25,436 GSK shares in Q1 2019, an estimated $1.22M.
Wolf Group Capital Advisors first reported a position in GSK in Q4 2015 and held it in 13 quarters.
Wolf Group Capital Advisors's GSK position peaked at $3.14M in Q2 2016.
848 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on Wolf Group Capital Advisors's 13F filing for Q1 2019, filed 22 Apr 2019.